LETRAZOLE LETRAZOLE LETRAZOLE LETRAZOLE LETRAZOLE LETRAZOLE
LETRAZOLE
LETRAZOLE LETRAZOLE LETRAZOLE LETRAZOLE LETRAZOLE

LETRAZOLE

450000 INR/Kilograms

Product Details:

  • Smell No Smell
  • Shelf Life 36 Months
  • Storage Room Temperature
  • Particle Size 10 MICRON
  • Molecular Formula C25H32F3N3O4
  • Taste Odorless
  • Loss on Drying 0.5 %
  • Click to View more
X

LETRAZOLE Price And Quantity

  • 450000 INR/Kilograms
  • 1 Kilograms

LETRAZOLE Product Specifications

  • 0.5 %
  • 495.534 Grams (g)
  • White crystalline powder
  • Odorless
  • 0.5 %
  • C25H32F3N3O4
  • Silodosin
  • 160970-54-7
  • Medicine Grade
  • ce silodosin has high affinity for the 1A adrenergic receptor, it causes practically no orthostatic hypotension (in contrast to other 1 blockers). On the other side, the high selectivity seems to be the cause of silodosin's typical side effect of loss of seminal emission.
  • 36 Months
  • No Smell
  • 99.8 %
  • Powder
  • Room Temperature
  • 10 MICRON
  • Cardiovascular Agents
  • Silodosin

LETRAZOLE Trade Information

  • SAHAR AIR CARGO
  • 100 Kilograms Per Month
  • 1 Days
  • Yes
  • Free samples are available
  • Double LDPE Liners in HDPE carboys
  • Chandigarh, Sikkim, Meghalaya, Andaman and Nicobar Islands, Nagaland, Uttarakhand, Dadra and Nagar Haveli, Lakshadweep, Bihar, Maharashtra, Daman and Diu, Assam, West India, Himachal Pradesh, Mizoram, Pondicherry, Kerala, Punjab, Goa, Jammu and Kashmir, West Bengal, Rajasthan, Telangana, Andhra Pradesh, Gujarat, Tamil Nadu, Tripura, Manipur, Chhattisgarh, South India, East India, Haryana, Arunachal Pradesh, Uttar Pradesh, Delhi, Madhya Pradesh, Karnataka, North India, Central India, Odisha, Jharkhand, All India
  • FDCA, GMP, GLP AND ISO

Product Description

Letrozole belongs to aromatase inhibitors class ofmedicine. Letrozole works by stopping the growth of breast cancer cell whichneeds estrogen to grow. Letrozole inhibits the estrogen level in body.

 

SYNONYSMS: Letrozole, Letrozol

 

IUPAC NAME:4-[(4-cyanophenyl)(1H-1,2,4-triazol-1-yl)methyl]benzonitrile

 

CAS NO: 112809-51-5

 

FORMULA: C17H11N5

 

MOLECULAR MASS: 285.30 g/mol

 

STORAGE CONDITIONS: Store the medicine in room temperature and dry place. Placethe medication away from direct heat and light. Do not keep medicine inbathroom or humid place. Keep away from children and pets.

 

HOW TO USE: Take themedicine orally once a day with or without food. Take medicine with milk orfood if you feel stomach upset. Take medication regularly to get most benefitsof it.

 

HOW LETROZOLE WORKS: Letrozole blocks the active site ofelectron transfer chain of CYP19A1. By this Letrozole inhibits the conversionof estrogen form androgen. By this Letrozole stops the growth of cancer cellswhich needs estrogen to grow.

 

PHARMACOKINETICS: Letrozole absorbed rapidly in body afteroral administration. Letrozole takes 8.10hpurs to reach peak plasmaconcentration. The bioavaibility of Letrozole is 99.9%. Almost 60% of medicinebinds with the plasma proteins. The half-life of this medicine is 42hours. Almost90% of Letrozole eliminated through urine.

 

SIDE EFFECTS OF LETROZOLE: The common side effects of Letrozole areheadache, nausea, vomiting, dizziness, sweating, tiredness, joint and musclepain. Tell your doctor if you see side effects like hot flushes, hair loss,bone fracture, swelling of arms or feet, blurred vision, dark urine. Seekimmediate medical attention if you see side effects like blood in cough,shortness of breath, arm or leg pain, stomach pain, dizziness, fainting, hairloss, vision change and sudden headache.

 

PRECAUTIONS: Tell your doctor if you have allergicreaction to the Letrozole medicine.

Tell your doctor if youhave history like heart disorder, liver problem, high BP, strokes, blood clotproblems. This drug makes you dizzy and because blurred vision so kindly avoiddriving, exercise, and operating machineries. Do not consume alcohol ormarijuana while taking the medicine.

 

CDSCO APPROVAL:LapatinibDitosylate Tablets 250mg (addl. Indication) approved by CDSCO in India in 10.05.2010
Letrozole 2.5mg tablet (additional indication) approved by CDSCO in India in28.12.2004

 Letrozole approved by CDSCOin India in 11.02.2002

 Palbociclib Capsules75mg/100mg/125 mg approved by CDSCO in India in11.08.2016

 Letrozole tabs approved byCDSCO in India in12.03.1998

Letrozole 2.5mg tablet (for additional indication)approved byCDSCO in India in 10.04.2007

 

FORMULATIONS AVAILABLE IN MARKET:

Letrozole 5mg tablets

Letrozole 2.5 mgtablets

 

Note: Product protected by valid patents are notoffered for sale in countries where such patents are still valid and itsliability is at Buyers Risk

 

REFERENCES:

 

www.webmd.com

https://pubchem.ncbi.nlm.nih.gov

https://go.drugbank.com

https://cdscoonline.gov.in

https://www.wikipedia.org/

https://www.drugs.com

https://www.zaubacorp.com

https://www.practo.com/consult

 

 

 

 

 

 

 

Tell us about your requirement
product

Price:

Quantity
Select Unit

  • 50
  • 100
  • 200
  • 250
  • 500
  • 1000+
Additional detail
Mobile number

Email

Other Products in 'Active Pharmaceuticals Ingredients (API)' category



trade india member
NIKSAN PHARMACEUTICAL All Rights Reserved.(Terms of Use)
Developed and Managed by Infocom Network Private Limited.